This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use
SAXENDA® safely and effectively. See full prescribing informationfor SAXENDA.
SAXENDA (liraglutide [rDNA origin] injection), solution for
subcutaneous use
Initial U.S. Approval: 2014
WARNING: RISK OF THYROID C-CELL TUMORS
See full prescribing information for complete boxed warning.
Liraglutide causes thyroid C-cell tumors at clinically relevant
exposures in both genders of rats and mice. It is unknown
whether Saxenda causes thyroid C-cell tumors, including
medullary thyroid carcinoma (MTC), in humans, as the humanrelevance of liraglutide-induced rodent thyroid C-cell tumors
has not been determined (5.1).

Saxenda is contraindicated in patients with a personal or family
history of MTC or in patients with Multiple Endocrine
Neoplasia syndrome type 2 (MEN 2). Counsel patients
regarding the risk of MTC and the symptoms of thyroid tumors(4, 5.1, 13.1).
································INDICATIONS AND USAGE··································
Saxenda is a glucagon-like peptide-1 (GLP-1) receptor agonist indicatedas an adjunct to a reduced-calorie diet and increased physical activity forchronic weight management in adult patients with an initial body massindex (BMI) of
30 kg/m2 or greater (obese) (1) or
27 kg/m2 or greater (overweight) in the presence of at least
one weight-related comorbid condition (e.g. hypertension,
type 2 diabetes mellitus, or dyslipidemia) (1).
Limitations of Use:
 Saxenda is not indicated for the treatment of type 2 diabetes (1).
 Saxenda should not be used in combination with any other GLP-1
receptor agonist (1).
 Saxenda should not be used with insulin (1, 5.4).
 The effects of Saxenda on cardiovascular morbidity and mortality
have not been established (1).
 The safety and efficacy of coadministration with other products forweight loss have not been established (1).
 Saxenda has not been studied in patients with a history of
pancreatitis (1, 5.2).
······························DOSAGE AND ADMINISTRATION·······················
 Recommended dose of Saxenda is 3 mg daily. Administer at any
time of day, without regard to the timing of meals (2).
 Initiate at 0.6 mg per day for one week. In weekly intervals,
increase the dose until a dose of 3 mg is reached (2).
 Inject subcutaneously in the abdomen, thigh or upper arm (2).
 The injection site and timing can be changed without dose
adjustment (2).

·······························DOSAGE FORMS AND STRENGTHS······························ Solution for subcutaneous injection, pre-filled, multi-dose pen that delivers
doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg or 3 mg (6 mg/mL, 3 mL) (3).
········································CONTRAINDICATIONS··············································
 Personal or family history of medullary thyroid carcinoma or Multiple
Endocrine Neoplasia syndrome type 2 (4, 5.1).
 Hypersensitivity to liraglutide or any product components (4, 5.7).
 Pregnancy (4, 8.1).
··································WARNINGS AND PRECAUTIONS······························
 Thyroid C-cell Tumors: Counsel patients regarding the risk of medullary
thyroid carcinoma and the symptoms of thyroid tumors (5.1).
 Acute Pancreatitis: Discontinue promptly if pancreatitis is suspected. Do
not restart if pancreatitis is confirmed (5.2).
 Acute Gallbladder Disease: If cholelithiasis or cholecystitis are suspected,
gallbladder studies are indicated (5.3).
 Serious Hypoglycemia: Can occur when Saxenda is used with an insulin
secretagogue (e.g. a sulfonylurea). Consider lowering the dose of antidiabetic drugs to reduce the risk of hypoglycemia (2, 5.4).
 Heart Rate Increase: Monitor heart rate at regular intervals (5.5).
 Renal Impairment: Has been reported postmarketing, usually in association
with nausea, vomiting, diarrhea, or dehydration which may sometimes
require hemodialysis. Use caution when initiating or escalating doses of
Saxenda in patients with renal impairment (5.6).
 Hypersensitivity Reactions: Postmarketing reports of serious
hypersensitivity reactions (e.g., anaphylactic reactions and angioedema).
Discontinue Saxenda and other suspect medications and promptly seek
medical advice (5.7).
 Suicidal Behavior and Ideation: Monitor for depression or suicidal thoughts.
Discontinue Saxenda if symptoms develop (5.8).
········································ADVERSE REACTIONS···········································
 Most common adverse reactions, reported in greater than or equal to 5%
are: nausea, hypoglycemia, diarrhea, constipation, vomiting, headache,decreased appetite, dyspepsia, fatigue, dizziness, abdominal pain, andincreased lipase (6.1).
To report SUSPECTED ADVERSE REACTIONS, contact Novo Nordisk
Inc. at 1-877-484-2869 or FDA at 1-800-FDA-1088 or
www.fda.gov/medwatch.
------------------------------DRUG INTERACTIONS---------------------------------- Saxenda delays gastric emptying. May impact absorption of concomitantly
administered oral medications. Use with caution (7).
····································USE IN SPECIFIC POPULATIONS·····························
 Nursing Mothers: Discontinue drug or nursing (8.3).
 Pediatric Use: Safety and effectiveness not established and use notrecommended (8.4).
See 17 for PATIENT COUNSELING INFORMATION and
Medication Guide.
Revised: 12/2014

1

Reference ID: 3677762

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

FULL PRESCRIBING INFORMATION: CONTENTS*
BOXED WARNING: RISK OF THYROID C-CELL TUMORS
1
2
3
4
5

6

7
8

INDICATIONS AND USAGE
DOSAGE AND ADMINISTRATIONDOSAGE FORMS AND STRENGTHSCONTRAINDICATIONSWARNINGS AND PRECAUTIONS
5.1 Risk of Thyroid C-cell Tumors
5.2 Acute Pancreatitis
5.3 Acute Gallbladder Disease
5.4 Risk for Hypoglycemia with Concomitant Use of
Anti-Diabetic Therapy
5.5 Heart Rate Increase
5.6 Renal Impairment
5.7 Hypersensitivity Reactions
5.8 Suicidal Behavior and Ideation
ADVERSE REACTIONS
6.1 Clinical Trials Experience
6.2 Postmarketing Experience
DRUG INTERACTIONS
7.1 Oral Medications
USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
8.3 Nursing Mothers
8.4 Pediatric Use
8.5 Geriatric Use
8.6 Renal Impairment
8.7 Hepatic Impairment

1

Reference ID: 3677762

8.8 Gastroparesis
OVERDOSAGEDESCRIPTION
CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
12.2 Pharmacodynamics
12.3 Pharmacokinetics
13
NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
14
CLINICAL STUDIES16
HOW SUPPLIED/STORAGE AND HANDLING
16.1 How Supplied
16.2 Recommended Storage
17
PATIENT COUNSELING INFORMATION
17.1 FDA-Approved Medication Guide
17.2 Instructions
17.3 Risk of Thyroid C-cell Tumors
17.4 Acute Pancreatitis
17.5 Acute Gallbladder Disease
17.6 Hypoglycemia in Patients with Type 2 Diabetes Mellitus on
Anti-Diabetic Therapy
17.7 Heart Rate Increase
17.8 Dehydration and Renal Impairment
17.9 Hypersensitivity Reactions
17.10 Suicidal Behavior and Ideation
17.11 Jaundice and Hepatitis
17.12 Never Share a Saxenda Pen Between Patients*Sections or subsections omitted from the full prescribing information are notlisted.
101112This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

FULL PRESCRIBING INFORMATIONWARNING: RISK OF THYROID C-CELL TUMORS
Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors atclinically relevant exposures in both genders of rats and mice. It is unknown whether Saxenda
causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as thehuman relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined[see Warnings and Precautions (5.1) and Nonclinical Toxicology (13.1)].
Saxenda is contraindicated in patients with a personal or family history of MTC and in patientswith Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding therisk of MTC with use of Saxenda and inform them of symptoms of thyroid tumors (e.g., a massin the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitoninor using thyroid ultrasound is of uncertain value for early detection of MTC in patients treatedwith Saxenda [see Contraindications (4), Warnings and Precautions (5.1)].

1
INDICATIONS AND USAGE
Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight
management in adult patients with an initial body mass index (BMI) of

30 kg/m2 or greater (obese), or
27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g.,
hypertension, type 2 diabetes mellitus, or dyslipidemia)

Limitations of Use Saxenda is not indicated for the treatment of type 2 diabetes mellitus.
 Saxenda and Victoza® both contain the same active ingredient, liraglutide, and therefore should not be used
together. Saxenda should not be used in combination with any other GLP-1 receptor agonist.
 Saxenda has not been studied in patients taking insulin. Saxenda and insulin should not be used together [seeWarnings and Precautions (5.4)].
 The effects of Saxenda on cardiovascular morbidity and mortality have not been established.
 The safety and effectiveness of Saxenda in combination with other products intended for weight loss,
including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established.
 Saxenda has not been studied in patients with a history of pancreatitis [see Warnings and Precautions (5.2)].
2
DOSAGE AND ADMINISTRATIONThe recommended dosage of Saxenda is 3 mg daily. The dose escalation schedule in Table 1 should be used toreduce the likelihood of gastrointestinal symptoms. If patients do not tolerate an increased dose during dose
escalation, consider delaying dose escalation for approximately one additional week. Saxenda should be
discontinued, however, if a patient cannot tolerate the 3 mg dose, as efficacy has not been established at lower
doses (0.6, 1.2, 1.8, and 2.4 mg).

1

Reference ID: 3677762

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

Table 1.

Dose Escalation Schedule
Week
1
2
3
4
5 and onward

Daily Dose
0.6 mg
1.2 mg
1.8 mg
2.4 mg
3 mg

Saxenda should be taken once daily at any time of day, without regard to the timing of meals. Saxenda can beinjected subcutaneously in the abdomen, thigh, or upper arm. The injection site and timing can be changed
without dose adjustment. Saxenda must not be administered intravenously or intramuscularly.
When initiating Saxenda in patients taking insulin secretagogues (such as sulfonylureas), consider reducing thedose of the insulin secretagogue (for example, by one-half) to reduce the risk for hypoglycemia, and monitor
blood glucose. Saxenda and insulin should not be used together [see Warnings and Precautions (5.4) and
Adverse Reactions (6.1)]. Conversely, if discontinuing Saxenda in patients with type 2 diabetes, monitor for an
increase in blood glucose.
Evaluate the change in body weight 16 weeks after initiating Saxenda and discontinue Saxenda if the patient has
not lost at least 4% of baseline body weight, since it is unlikely that the patient will achieve and sustain
clinically meaningful weight loss with continued treatment.
If a dose is missed, the once-daily regimen should be resumed as prescribed with the next scheduled dose. An
extra dose or increase in dose should not be taken to make up for the missed dose. If more than 3 days haveelapsed since the last Saxenda dose, patients should reinitiate Saxenda at 0.6 mg daily and follow the dose
escalation schedule in Table 1, which may reduce the occurrence of gastrointestinal symptoms associated withreinitiation of treatment.
Prior to initiation of Saxenda, patients should be trained by their healthcare professional on proper injection
technique. Training reduces the risk of administration errors such as needle sticks and incomplete dosing. Referto the accompanying Instructions for Use for complete administration instructions with illustrations.
Saxenda solution should be inspected prior to each injection, and the solution should be used only if it is clear,colorless, and contains no particles.
BMI is calculated by dividing weight in (kilograms) by height (in meters) squared. A chart for determining BMI
based on height and weight is provided in Table 2.

1

Reference ID: 3677762

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

Table 2.

BMI Conversion Chart

3
DOSAGE FORMS AND STRENGTHS
Solution for subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4
mg, or 3 mg (6 mg/mL, 3 mL).
4
CONTRAINDICATIONS
Saxenda is contraindicated in the following conditions: Patients with a personal or family history of medullary thyroid carcinoma (MTC) or patients with
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions (5.1)]
 Patients with a prior serious hypersensitivity reaction to liraglutide or to any of the product components[see Warnings and Precautions (5.7)]
 Pregnancy [see Use in Specific Populations (8.1)]
5
WARNINGS AND PRECAUTIONS
5.1
Risk of Thyroid C-cell Tumors
Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors (adenomas
and/or carcinomas) at clinically relevant exposures in both genders of rats and mice [see Nonclinical
Toxicology (13.1)]. Malignant thyroid C-cell carcinomas were detected in rats and mice. It is unknown whether
Saxenda will cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as thehuman relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined.
Cases of MTC in patients treated with liraglutide have been reported in the postmarketing period; the data inthese reports are insufficient to establish or exclude a causal relationship between MTC and liraglutide use in
humans.
Saxenda is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2.
Counsel patients regarding the risk for MTC and inform them of symptoms of thyroid tumors (e.g., a mass inthe neck, dysphagia, dyspnea, persistent hoarseness).
1

Reference ID: 3677762

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of
MTC in patients treated with Saxenda. Such monitoring may increase the risk of unnecessary procedures, due
to low test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly
elevated serum calcitonin may indicate MTC, and patients with MTC usually have calcitonin values greaterthan 50 ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated.
Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated.
5.2
Acute Pancreatitis
Based on spontaneous postmarketing reports, acute pancreatitis, including fatal and non-fatal hemorrhagic or
necrotizing pancreatitis, has been observed in patients treated with liraglutide. After initiation of Saxenda,
observe patients carefully for signs and symptoms of pancreatitis (including persistent severe abdominal pain,
sometimes radiating to the back and which may or may not be accompanied by vomiting). If pancreatitis issuspected, Saxenda should promptly be discontinued and appropriate management should be initiated. If
pancreatitis is confirmed, Saxenda should not be restarted.
In Saxenda clinical trials, acute pancreatitis was confirmed by adjudication in 9 (0.3%) of 3291 Saxenda-treatedpatients and 1 (0.1%) of 1843 placebo-treated patients. In addition, there were 2 cases of acute pancreatitis in
Saxenda-treated patients who prematurely withdrew from these clinical trials, occurring 74 and 124 days after
the last dose, and 1 additional case in a Saxenda-treated patient during an off-treatment follow-up period within
2 weeks of discontinuing Saxenda.
It is unknown whether patients with a history of pancreatitis are at increased risk for pancreatitis while using
Saxenda, since these patients were excluded from clinical trials.
5.3
Acute Gallbladder Disease
In Saxenda clinical trials, 1.5% of Saxenda-treated patients reported adverse events of cholelithiasis versus
0.5% of placebo-treated patients. The incidence of cholecystitis was 0.6% in Saxenda-treated patients versus
0.2% in placebo-treated patients. The majority of Saxenda-treated patients with adverse events of cholelithiasis
and cholecystitis required cholecystectomy. Substantial or rapid weight loss can increase the risk ofcholelithiasis; however, the incidence of acute gallbladder disease was greater in Saxenda-treated patients thanin placebo-treated patients even after accounting for the degree of weight loss. If cholelithiasis is suspected,
gallbladder studies and appropriate clinical follow-up are indicated.
5.4
Risk for Hypoglycemia with Concomitant Use of Anti-Diabetic Therapy
The risk for serious hypoglycemia is increased when Saxenda is used in combination with insulin secretagogues(for example, sulfonylureas) in patients with type 2 diabetes mellitus. Therefore, patients may require a lower
dose of sulfonylurea (or other concomitantly administered insulin secretagogues) in this setting [see Dosage
and Administration (2) and Adverse Reactions (6.1)]. Saxenda should not be used in patients taking insulin.
Saxenda can lower blood glucose [see Clinical Pharmacology (12.2)]. Monitor blood glucose parameters prior
to starting Saxenda and during Saxenda treatment in patients with type 2 diabetes. If needed, adjust coadministered anti-diabetic drugs based on glucose monitoring results and risk of hypoglycemia.
5.5Heart Rate Increase
Mean increases in resting heart rate of 2 to 3 beats per minute (bpm) were observed with routine clinicalmonitoring in Saxenda-treated patients compared to placebo in clinical trials. More patients treated with
Saxenda, compared with placebo, had changes from baseline at two consecutive visits of more than 10 bpm(34% versus 19%, respectively) and 20 bpm (5% versus 2%, respectively). At least one resting heart rate
exceeding 100 bpm was recorded for 6% of Saxenda-treated patients compared with 4% of placebo-treated1

Reference ID: 3677762

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

patients, with this occurring at two consecutive study visits for 0.9% and 0.3%, respectively. Tachycardia wasreported as an adverse reaction in 0.6% of Saxenda-treated patients and in 0.1% of placebo-treated patients.
In a clinical pharmacology trial that monitored heart rate continuously for 24 hours, Saxenda treatment was
associated with a heart rate that was 4 to 9 bpm higher than that observed with placebo.
The clinical significance of the heart rate elevation with Saxenda treatment is unclear, especially for patientswith cardiac and cerebrovascular disease as a result of limited exposure in these patients in clinical trials.
Heart rate should be monitored at regular intervals consistent with usual clinical practice. Patients should inform
health care providers of palpitations or feelings of a racing heartbeat while at rest during Saxenda treatment. For
patients who experience a sustained increase in resting heart rate while taking Saxenda, Saxenda should be
discontinued.
5.6
Renal Impairment
In patients treated with GLP-1 receptor agonists, including Saxenda, there have been reports of acute renal
failure and worsening of chronic renal failure, sometimes requiring hemodialysis [see Adverse Reactions (6.2)].
Some of these events were reported in patients without known underlying renal disease. A majority of thereported events occurred in patients who had experienced nausea, vomiting, or diarrhea leading to volume
depletion. Some of the reported events occurred in patients receiving one or more medications known to affectrenal function or volume status. Altered renal function has been reversed in many of the reported cases withsupportive treatment and discontinuation of potentially causative agents, including liraglutide. Use caution
when initiating or escalating doses of Saxenda in patients with renal impairment [see Use in Specific
Populations (8.6)].
5.7
Hypersensitivity Reactions
There have been reports of serious hypersensitivity reactions (e.g., anaphylactic reactions and angioedema) inpatients treated with liraglutide [see Adverse Reactions (6.1, 6.2)]. If a hypersensitivity reaction occurs, thepatient should discontinue Saxenda and other suspect medications and promptly seek medical advice.
Angioedema has also been reported with other GLP-1 receptor agonists. Use caution in a patient with ahistory of angioedema with another GLP-1 receptor agonist because it is unknown whether such patients
will be predisposed to angioedema with Saxenda.
5.8
Suicidal Behavior and Ideation
In Saxenda clinical trials, 6 (0.2%) of 3384 Saxenda-treated patients and none of the 1941 placebo-treatedpatients reported suicidal ideation; one of these Saxenda-treated patients attempted suicide. Patients treated with
Saxenda should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior,
and/or any unusual changes in mood or behavior. Discontinue Saxenda in patients who experience suicidal
thoughts or behaviors. Avoid Saxenda in patients with a history of suicidal attempts or active suicidal ideation.
6
ADVERSE REACTIONS
The following serious adverse reactions are described below or elsewhere in the prescribing information:
 Risk of Thyroid C-Cell Tumors [see Warnings and Precautions (5.1)]
 Acute Pancreatitis [see Warnings and Precautions (5.2)]
 Acute Gallbladder Disease [see Warnings and Precautions (5.3)]
 Risk for Hypoglycemia with Concomitant Use of Anti-Diabetic Therapy [see Warnings and Precautions(5.4)]
 Heart Rate Increase [see Warnings and Precautions (5.5)]
1

Reference ID: 3677762

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

Renal Impairment [see Warnings and Precautions (5.6)]
Hypersensitivity Reactions [see Warnings and Precautions (5.7)]
Suicidal Behavior and Ideation [see Warnings and Precautions (5.8)]

6.1
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in theclinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may notreflect the rates observed in practice.
Saxenda was evaluated for safety in 5 double-blind, placebo controlled trials that included 3384 overweight orobese patients treated with Saxenda for a treatment period up to 56 weeks (3 trials), 52 weeks (1 trial), and 32
weeks (1 trial). All patients received study drug in addition to diet and exercise counseling. In these trials,
patients received Saxenda for a mean treatment duration of 45.9 weeks (median, 55.9 weeks). Of these, 1087
Saxenda-treated patients and 497 placebo-treated patients have been exposed in their original randomized
groups beyond the primary endpoint for an additional mean duration of 53.0 weeks (median, 56.9 weeks).
Baseline characteristics included a mean age of 47 years, 71% women, 85% white, 39% with hypertension, 15%with type 2 diabetes, 34% with dyslipidemia, 29% with a BMI greater than 40 kg/m2, and 9% withcardiovascular disease. Dosing was initiated and increased weekly to reach the 3 mg dose.
In clinical trials, 9.8% of patients treated with Saxenda and 4.3% of patients treated with placebo prematurely
discontinued treatment as a result of adverse reactions. The most common adverse reactions leading todiscontinuation were nausea (2.9% versus 0.2% for Saxenda and placebo, respectively), vomiting (1.7% versus
less than 0.1%), and diarrhea (1.4% versus 0%).
Adverse reactions reported in greater than or equal to 2% of Saxenda-treated patients and more frequently thanin placebo-treated patients are shown in Table 3.
Table 3.

Adverse Reactions Reported in Greater Than or Equal to 2% of Saxenda-treated Patientsand More Frequently than with Placebo
Placebo
SaxendaN = 1941
N = 3384%%
Gastrointestinal Disorders
Nausea13.8
39.3
Diarrhea
9.9
20.9
Constipation
8.5
19.4
Vomiting
3.9
15.7
Dyspepsia
2.7
9.6
Abdominal Pain
3.1
5.4
Upper Abdominal Pain
2.7
5.1
Gastroesophageal Reflux Disease
1.7
4.7
Abdominal Distension
3.0
4.5
Eructation
0.2
4.5
Flatulence
2.5
4.0
Dry Mouth
1.0
2.3
Metabolism and Nutrition Disorders
Hypoglycemia in T2DM1
12.7
23.0
Decreased Appetite
2.3
10.0
Nervous System Disorders
1

Reference ID: 3677762

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

HeadacheDizziness
General Disorders and Administration Site
Conditions
Fatigue
Injection site Erythema
Injection Site Reaction
Asthenia
Infections and Infestations
Gastroenteritis
Urinary Tract Infection
Viral Gastroenteritis
Investigations
Increased Lipase
Psychiatric Disorders
Insomnia
Anxiety
1

12.6
5.0

13.6
6.9

4.6
0.2
0.6
0.8

7.5
2.5
2.5
2.1

3.2
3.1
1.6

4.7
4.3
2.8

2.2

5.3

1.7
1.6

2.4
2.0

Documented symptomatic (defined as documented symptoms of hypoglycemia in combination with a plasma glucose less than orequal to 70 mg/dL) in patients with type 2 diabetes (Study 2). See text below for further information regarding hypoglycemia inpatients with and without type 2 diabetes. T2DM = type 2 diabetes mellitus

Hypoglycemia
Saxenda can lower blood glucose. In a clinical trial involving patients with type 2 diabetes mellitus andoverweight or obesity, severe hypoglycemia (defined as requiring the assistance of another person) occurred in
3 (0.7%) of 422 Saxenda-treated patients and in none of the 212 placebo-treated patients. Each of these 3
Saxenda-treated patients was also taking a sulfonylurea. In the same trial, among patients taking a sulfonylurea,
documented symptomatic hypoglycemia (defined as documented symptoms of hypoglycemia in combination
with a plasma glucose less than or equal to 70 mg/dL) occurred in 48 (43.6%) of 110 Saxenda-treated patientsand 15 (27.3%) of 55 placebo-treated patients. The doses of sulfonylureas were reduced by 50% at the
beginning of the trial per protocol. The frequency of hypoglycemia may be higher if the dose of sulfonylurea is
not reduced. Among patients not taking a sulfonylurea, documented symptomatic hypoglycemia occurred in 49(15.7%) of 312 Saxenda-treated patients and 12 (7.6%) of 157 placebo-treated patients.
In Saxenda clinical trials involving patients without type 2 diabetes mellitus, there was no systematic capturing
or reporting of hypoglycemia, as patients were not provided with blood glucose meters or hypoglycemia diaries.
Spontaneously reported symptomatic episodes of unconfirmed hypoglycemia were reported by 46 (1.6%) of
2962 Saxenda-treated patients and 19 (1.1%) of 1729 placebo-treated patients. Fasting plasma glucose values
obtained at routine clinic visits less than or equal to 70 mg/dL, irrespective of hypoglycemic symptoms, werereported as “hypoglycemia” in 92 (3.1%) Saxenda-treated patients and 13 (0.8%) placebo-treated patients.
Gastrointestinal Adverse Reactions
In the clinical trials, approximately 68% of Saxenda-treated patients and 39% of placebo-treated patients
reported gastrointestinal disorders; the most frequently reported was nausea (39% and 14% of patients treatedwith Saxenda and placebo, respectively). The percentage of patients reporting nausea declined as treatment
continued. Other common adverse reactions that occurred at a higher incidence among Saxenda-treated patients
included diarrhea, constipation, vomiting, dyspepsia, abdominal pain, dry mouth, gastritis, gastroesophageal
reflux disease, flatulence, eructation and abdominal distension. Most episodes of gastrointestinal events weremild or moderate and did not lead to discontinuation of therapy (6.2% with Saxenda versus 0.8% with placebo
discontinued treatment as a result of gastrointestinal adverse reactions). There have been reports of1

Reference ID: 3677762

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

gastrointestinal adverse reactions, such as nausea, vomiting, and diarrhea, associated with volume depletion andrenal impairment [see Warnings and Precautions (5.6)].
Asthenia, Fatigue, Malaise, Dysgeusia and Dizziness
Events of asthenia, fatigue, malaise, dysgeusia and dizziness were mainly reported within the first 12 weeks oftreatment with Saxenda and were often co-reported with gastrointestinal events such as nausea, vomiting, anddiarrhea.
Immunogenicity
Patients treated with Saxenda may develop anti-liraglutide antibodies. Anti-liraglutide antibodies were detected
in 42 (2.8%) of 1505 Saxenda-treated patients with a post-baseline assessment. Antibodies that had aneutralizing effect on liraglutide in an in vitro assay occurred in 18 (1.2%) of 1505 Saxenda-treated patients.
Presence of antibodies may be associated with a higher incidence of injection site reactions and reports of low
blood glucose. In clinical trials, these events were usually classified as mild and resolved while patients
continued on treatment.
The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay.
Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be
influenced by several factors including assay methodology, sample handling, timing of sample collection,
concomitant medications, and underlying disease. For these reasons, the incidence of antibodies to Saxenda
cannot be directly compared with the incidence of antibodies of other products.
Allergic reactions
Urticaria was reported in 0.7% of Saxenda-treated patients and 0.5% of placebo-treated patients. Anaphylactic
reactions, asthma, bronchial hyperreactivity, bronchospasm, oropharyngeal swelling, facial swelling,angioedema, pharyngeal edema, type IV hypersensitivity reactions have been reported in patients treated withliraglutide in clinical trials. Cases of anaphylactic reactions with additional symptoms such as hypotension,
palpitations, dyspnea, and edema have been reported with marketed use of liraglutide. Anaphylactic reactions
may potentially be life-threatening.
Injection site reactions
Injection site reactions were reported in approximately 13.9% of Saxenda-treated patients and 10.5% ofplacebo-treated patients. The most common reactions, each reported by 1% to 2.5% of Saxenda-treated patientsand more commonly than by placebo-treated patients, included erythema, pruritus, and rash at the injection site.
0.6% of Saxenda-treated patients and 0.5% of placebo-treated patients discontinued treatment due to injection
site reactions.
Breast Cancer
In Saxenda clinical trials breast cancer confirmed by adjudication was reported in 14 (0.6%) of 2379 Saxendatreated women compared with 3 (0.2%) of 1300 placebo-treated women, including invasive cancer (11Saxenda- and 2 placebo-treated women) and ductal carcinoma in situ (3 Saxenda- and 1 placebo-treatedwoman). The majority of cancers were estrogen- and progesterone-receptor positive. There were too few cases
to determine whether these cases were related to Saxenda. In addition, there are insufficient data to determine
whether Saxenda has an effect on pre-existing breast neoplasia.
Papillary Thyroid Cancer
In Saxenda clinical trials, papillary thyroid carcinoma confirmed by adjudication was reported in 7 (0.2%) of
3291 Saxenda-treated patients compared with no cases among 1843 placebo-treated patients. Four of these
papillary thyroid carcinomas were less than 1 cm in greatest diameter and 4 were diagnosed in surgicalpathology specimens after thyroidectomy prompted by findings identified prior to treatment.
1

Reference ID: 3677762

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

Colorectal Neoplasms
In Saxenda clinical trials, benign colorectal neoplasms (mostly colon adenomas) confirmed by adjudication
were reported in 17 (0.5%) of 3291 Saxenda-treated patients compared with 4 (0.2%) of 1843 placebo-treatedpatients. Two positively adjudicated cases of malignant colorectal carcinoma were reported in Saxenda-treatedpatients (0.1%) and none in placebo-treated patients.
Cardiac Conduction Disorders
In Saxenda clinical trials, 11 (0.3%) of 3384 Saxenda-treated patients compared with none of the 1941 placebotreated patients had a cardiac conduction disorder, reported as first degree atrioventricular block, right bundle
branch block, or left bundle branch block.
Hypotension
Adverse reactions related to hypotension (that is, reports of hypotension, orthostatic hypotension, circulatory
collapse, and decreased blood pressure) were reported more frequently with Saxenda (1.1%) compared withplacebo (0.5%) in Saxenda clinical trials. Systolic blood pressure decreases to less than 80 mmHg wereobserved in 4 (0.1%) Saxenda-treated patients compared with no placebo-treated patients. One of the Saxendatreated patients had hypotension associated with gastrointestinal adverse reactions and renal failure [seeWarnings and Precautions (5.6)].
Laboratory Abnormalities
Liver Enzymes
Increases in alanine aminotransferase (ALT) greater than or equal to 10 times the upper limit of normal wereobserved in 5 (0.15%) Saxenda-treated patients (two of whom had ALT greater than 20 and 40 times the upper
limit of normal) compared with 1 (0.05%) placebo-treated patient during the Saxenda clinical trials. Becauseclinical evaluation to exclude alternative causes of ALT and aspartate aminotransferase (AST) increases was notdone in most cases, the relationship to Saxenda is uncertain. Some increases in ALT and AST were associatedwith other confounding factors (such as gallstones).
Serum Calcitonin
Calcitonin, a biological marker of MTC, was measured throughout the clinical development program [seeWarnings and Precautions (5.1)]. More patients treated with Saxenda in the clinical trials were observed tohave high calcitonin values during treatment, compared with placebo. The proportion of patients with calcitoningreater than or equal to 2 times the upper limit of normal at the end of the trial was 1.2% in Saxenda-treatedpatients and 0.6% in placebo-treated patients. Calcitonin values greater than 20 ng/L at the end of the trial
occurred in 0.5% of Saxenda-treated patients and 0.2% of placebo-treated patients; among patients with pretreatment serum calcitonin less than 20 ng/L, none had calcitonin elevations to greater than 50 ng/L at the endof the trial.
Serum Lipase and Amylase
Serum lipase and amylase were routinely measured in the Saxenda clinical trials. Among Saxenda-treatedpatients, 2.1% had a lipase value at anytime during treatment of greater than or equal to 3 times the upper limit
of normal compared with 1.0% of placebo-treated patients. 0.1% of Saxenda-treated patients had an amylase
value at anytime in the trial of greater than or equal to 3 times the upper limit of normal versus 0.1% of placebotreated patients. The clinical significance of elevations in lipase or amylase with Saxenda is unknown in theabsence of other signs and symptoms of pancreatitis [see Warnings and Precautions (5.2)].
6.2

Post-Marketing Experience

1

Reference ID: 3677762

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

The following adverse reactions have been reported during post-approval use of liraglutide, the active
ingredient of Saxenda. Because these reactions are reported voluntarily from a population of uncertain size, it is
not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Neoplasms
Medullary thyroid carcinoma [see Warnings and Precautions (5.1)]
Gastrointestinal Disorders
Acute pancreatitis, hemorrhagic and necrotizing pancreatitis, sometimes resulting in death [seeWarnings and Precautions (5.2)]
Metabolism and Nutrition Disorders
Dehydration resulting from nausea, vomiting and diarrhea [see Adverse Reactions (6.1)]
Renal and Urinary Disorders
Increased serum creatinine, acute renal failure or worsening of chronic renal failure, sometimes
requiring hemodialysis [see Warnings and Precautions (5.6)]
General Disorders and Administration Site Conditions
Allergic reactions: rash and pruritus [see Adverse Reactions (6.1)]
Immune System Disorders
Angioedema and anaphylactic reactions [see Warnings and Precautions (5.7)]
Hepatobiliary Disorders
Elevations of liver enzymes, hyperbilirubinemia, cholestasis and hepatitis [see Adverse Reactions (6.1)]
7
DRUG INTERACTIONS
7.1
Oral Medications
Saxenda causes a delay of gastric emptying, and thereby has the potential to impact the absorption of
concomitantly administered oral medications. In clinical pharmacology trials, liraglutide did not affect theabsorption of the tested orally administered medications to any clinically relevant degree. Nonetheless, monitor
for potential consequences of delayed absorption of oral medications concomitantly administered with Saxenda.
8
USE IN SPECIFIC POPULATIONS
8.1
Pregnancy
Pregnancy Category X.
Risk Summary
Saxenda is contraindicated during pregnancy because weight loss offers no potential benefit to a pregnant
woman and may result in fetal harm. There are no adequate and well-controlled studies of Saxenda in pregnant
women. Saxenda should not be used during pregnancy. If a patient wishes to become pregnant, or pregnancy
occurs, treatment with Saxenda should be discontinued.
Clinical Considerations
A minimum weight gain, and no weight loss, is recommended for all pregnant women, including those who are
already overweight or obese, due to the necessary weight gain that occurs in maternal tissues during pregnancy.
Animal Data
Liraglutide has been shown to be teratogenic in rats at or above 0.8-times systemic exposures in obese humans
resulting from the maximum recommended human dose (MRHD) of 3 mg/day based on plasma area under thetime-concentration curve (AUC) comparison. Liraglutide has been shown to cause reduced growth andincreased total major abnormalities in rabbits at systemic exposures below exposure in obese humans at the
MRHD based on plasma AUC comparison.

1

Reference ID: 3677762

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

Female rats given subcutaneous doses of 0.1, 0.25 and 1 mg/kg/day liraglutide beginning 2 weeks before mating
through gestation day 17 had estimated systemic exposures 0.8-, 3-, and 11-times the exposure in obese
humans at the MRHD based on plasma AUC comparison. The number of early embryonic deaths in the 1
mg/kg/day group increased slightly. Fetal abnormalities and variations in kidneys and blood vessels, irregularossification of the skull, and a more complete state of ossification occurred at all doses. Mottled liver andminimally kinked ribs occurred at the highest dose. The incidence of fetal malformations in liraglutide-treatedgroups exceeding concurrent and historical controls were misshapen oropharynx and/or narrowed opening intolarynx at 0.1 mg/kg/day and umbilical hernia at 0.1 and 0.25 mg/kg/day.
Pregnant rabbits given subcutaneous doses of 0.01, 0.025 and 0.05 mg/kg/day liraglutide from gestation day 6
through day 18 inclusive, had estimated systemic exposures less than the exposure in obese humans at the
MRHD of 3 mg/day at all doses, based on plasma AUC comparison. Liraglutide decreased fetal weight anddose-dependently increased the incidence of total major fetal abnormalities at all doses. The incidence ofmalformations exceeded concurrent and historical controls at 0.01 mg/kg/day (kidneys, scapula), greater than orequal to 0.01 mg/kg/day (eyes, forelimb), 0.025 mg/kg/day (brain, tail and sacral vertebrae, major blood vessels
and heart, umbilicus), greater than or equal to 0.025 mg/kg/day (sternum) and at 0.05 mg/kg/day (parietal
bones, major blood vessels). Irregular ossification and/or skeletal abnormalities occurred in the skull and jaw,
vertebrae and ribs, sternum, pelvis, tail, and scapula; and dose-dependent minor skeletal variations wereobserved. Visceral abnormalities occurred in blood vessels, lung, liver, and esophagus. Bilobed or bifurcatedgallbladder was seen in all treatment groups, but not in the control group.
In pregnant female rats given subcutaneous doses of 0.1, 0.25 and 1 mg/kg/day liraglutide from gestation day 6
through weaning or termination of nursing on lactation day 24, estimated systemic exposures were 0.8-, 3-, and11-times exposure in obese humans at the MRHD of 3 mg/day, based on plasma AUC comparison. A slightdelay in parturition was observed in the majority of treated rats. Group mean body weight of neonatal rats fromliraglutide-treated dams was lower than neonatal rats from control group dams. Bloody scabs and agitatedbehavior occurred in male rats descended from dams treated with 1 mg/kg/day liraglutide. Group mean bodyweight from birth to postpartum day 14 trended lower in F2 generation rats descended from liraglutide-treatedrats compared to F2 generation rats descended from controls, but differences did not reach statisticalsignificance for any group.
8.3
Nursing Mothers
It is not known whether Saxenda is excreted in human milk. Because many drugs are excreted in human milk
and because of the potential for tumorigenicity shown for liraglutide in animal studies, a decision should bemade whether to discontinue nursing or to discontinue Saxenda, taking into account the importance of the drug
to the mother. In lactating rats, liraglutide was excreted unchanged in milk at concentrations approximately 50%
of maternal plasma concentrations.
8.4
Pediatric Use
Safety and effectiveness of Saxenda have not been established in pediatric patients. Saxenda is notrecommended for use in pediatric patients.
8.5
Geriatric Use
In the Saxenda clinical trials, 232 (6.9%) of the Saxenda-treated patients were 65 years of age and over, and 17(0.5%) of the Saxenda-treated patients were 75 years of age and over. No overall differences in safety oreffectiveness were observed between these patients and younger patients, but greater sensitivity of some older
individuals cannot be ruled out.
8.6

Renal Impairment
1

Reference ID: 3677762

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

There is limited experience with Saxenda in patients with mild, moderate, and severe renal impairment,
including end-stage renal disease. However, there have been postmarketing reports of acute renal failure andworsening of chronic renal failure with liraglutide, which may sometimes require hemodialysis [see Warnings
and Precautions (5.6) and Adverse Reactions (6.2)]. Saxenda should be used with caution in this patient
population [see Clinical Pharmacology (12.3)].
8.7
Hepatic Impairment
There is limited experience in patients with mild, moderate, or severe hepatic impairment. Therefore, Saxenda
should be used with caution in this patient population [see Clinical Pharmacology (12.3)].
8.8
Gastroparesis
Saxenda slows gastric emptying. Saxenda has not been studied in patients with pre-existing gastroparesis.
10
OVERDOSAGE
Overdoses have been reported in clinical trials and post-marketing use of liraglutide. Effects have included
severe nausea and severe vomiting. In the event of overdosage, appropriate supportive treatment should
be initiated according to the patient’s clinical signs and symptoms.
11
DESCRIPTION
Saxenda contains liraglutide, an analog of human GLP-1 and acts as a GLP-1 receptor agonist. The peptide
precursor of liraglutide, produced by a process that includes expression of recombinant DNA in Saccharomyces
cerevisiae, has been engineered to be 97% homologous to native human GLP-1 by substituting arginine forlysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acidspacer on the remaining lysine residue at position 26 of the peptide precursor. The molecular formula ofliraglutide is C172H265N43O51 and the molecular weight is 3751.2 Daltons. The structural formula (Figure 1) is:

Figure 1.

Structural Formula of liraglutide

Saxenda is a clear, colorless solution. Each 1 mL of Saxenda solution contains 6 mg of liraglutide and thefollowing inactive ingredients: disodium phosphate dihydrate, 1.42 mg; propylene glycol, 14 mg; phenol, 5.5
mg; and water for injection. Each pre-filled pen contains a 3 mL solution of Saxenda equivalent to 18 mg
liraglutide (free-base, anhydrous).
12
CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Liraglutide is an acylated human glucagon-like peptide-1 (GLP-1) receptor agonist with 97% amino acidsequence homology to endogenous human GLP-1(7-37). Like endogenous GLP-1, liraglutide binds to andactivates the GLP-1 receptor, a cell-surface receptor coupled to adenylyl cyclase activation through thestimulatory G-protein, Gs. Endogenous GLP-1 has a half-life of 1.5-2 minutes due to degradation by the1

Reference ID: 3677762

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

ubiquitous endogenous enzymes, dipeptidyl peptidase 4 (DPP-4) and neutral endopeptidases (NEP). Unlike
native GLP-1, liraglutide is stable against metabolic degradation by both peptidases and has a plasma half-lifeof 13 hours after subcutaneous administration. The pharmacokinetic profile of liraglutide, which makes itsuitable for once-daily administration, is a result of self-association that delays absorption, plasma protein
binding, and stability against metabolic degradation by DPP-4 and NEP.
GLP-1 is a physiological regulator of appetite and calorie intake, and the GLP-1 receptor is present in several
areas of the brain involved in appetite regulation. In animal studies, peripheral administration of liraglutide
resulted in the presence of liraglutide in specific brain regions regulating appetite, including the hypothalamus.
Although liraglutide activated neurons in brain regions known to regulate appetite, specific brain regions
mediating the effects of liraglutide on appetite were not identified in rats.
12.2 Pharmacodynamics
Liraglutide lowers body weight through decreased calorie intake. Liraglutide does not increase 24-hour energy
expenditure.
As with other GLP-1 receptor agonists, liraglutide stimulates insulin secretion and reduces glucagon secretionin a glucose-dependent manner. These effects can lead to a reduction of blood glucose.
Cardiac Electrophysiology (QTc) in healthy volunteers
The effect of liraglutide on cardiac repolarization was tested in a QTc study. Liraglutide at steady-state
concentrations after daily doses up to 1.8 mg did not produce QTc prolongation. The maximum liraglutide
plasma concentration (Cmax) in overweight and obese subjects treated with liraglutide 3 mg is similar to the Cmax
observed in the liraglutide QTc study in healthy volunteers.
12.3 Pharmacokinetics
Absorption - Following subcutaneous administration, maximum concentrations of liraglutide are achieved at 11
hours post dosing. The average liraglutide steady state concentration (AUCτ/24) reached approximately 116
ng/mL in obese (BMI 30-40 kg/m2) subjects following administration of Saxenda. Liraglutide exposure
increased proportionally in the dose range of 0.6 mg to 3 mg. The intra-subject coefficient of variation forliraglutide AUC was 11% following single dose administration. Liraglutide exposures were considered similar
among three subcutaneous injection sites (upper arm, abdomen, and thigh). Absolute bioavailability ofliraglutide following subcutaneous administration is approximately 55%.
Distribution - The mean apparent volume of distribution after subcutaneous administration of liraglutide 3 mg is
20-25 L (for a person weighing approximately 100 kg). The mean volume of distribution after intravenous
administration of liraglutide is 0.07 L/kg. Liraglutide is extensively bound to plasma protein (greater than 98%).
Metabolism - During the initial 24 hours following administration of a single [3H]-liraglutide dose to healthy
subjects, the major component in plasma was intact liraglutide. Liraglutide is endogenously metabolized in asimilar manner to large proteins without a specific organ as a major route of elimination.
Elimination - Following a [3H]-liraglutide dose, intact liraglutide was not detected in urine or feces. Only aminor part of the administered radioactivity was excreted as liraglutide-related metabolites in urine or feces (6%and 5%, respectively). The majority of urine and feces radioactivity was excreted during the first 6-8 days. The
mean apparent clearance following subcutaneous administration of a single dose of liraglutide is approximately
0.9-1.4 L/h with an elimination half-life of approximately 13 hours, making liraglutide suitable for once dailyadministration.
Specific Populations
1

Reference ID: 3677762

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

Elderly - No dosage adjustment is required based on age. Age had no effect on the pharmacokinetics ofliraglutide based on a pharmacokinetic study in healthy elderly subjects (65 to 83 years) and population
pharmacokinetic analyses of data from overweight and obese patients 18 to 82 years of age [see Use in Specific
Populations (8.5)].
Gender - Based on the results of population pharmacokinetic analyses, females have 24% lower weight adjusted
clearance of Saxenda compared to males. Based on the exposure response data, no dose adjustment is necessary
based on gender.
Race and Ethnicity - Race and ethnicity had no effect on the pharmacokinetics of liraglutide based on the resultsof population pharmacokinetic analyses that included overweight and obese patients of Caucasian, Black, Asianand Hispanic/Non-Hispanic groups.
Body Weight - Body weight significantly affects the pharmacokinetics of liraglutide based on results of
population pharmacokinetic analyses conducted in patients with body weight range of 60-234 kg. The exposureof liraglutide decreases as baseline body weight increases.
Pediatric - Saxenda has not been studied in pediatric patients [see Use in Specific Populations (8.4)].
Renal Impairment - The single-dose pharmacokinetics of liraglutide were evaluated in subjects with varying
degrees of renal impairment. Subjects with mild (estimated creatinine clearance 50-80 mL/min) to severe(estimated creatinine clearance less than 30 mL/min) renal impairment and subjects with end-stage renal diseaserequiring dialysis were included in the trial. Compared to healthy subjects, liraglutide AUC in mild, moderate,and severe renal impairment and in end-stage renal disease was on average 35%, 19%, 29% and 30% lower,
respectively [see Use in Specific Populations (8.6)].
Hepatic Impairment - The single-dose pharmacokinetics of liraglutide were evaluated in subjects with varying
degrees of hepatic impairment. Subjects with mild (Child Pugh score 5-6) to severe (Child Pugh score greaterthan 9) hepatic impairment were included in the trial. Compared to healthy subjects, liraglutide AUC in subjects
with mild, moderate and severe hepatic impairment was on average 11%, 14% and 42% lower, respectively [seeUse in Specific Populations (8.7)].
Drug Interactions
In vitro assessment of drug−drug interactions
Liraglutide has low potential for pharmacokinetic drug-drug interactions related to cytochrome P450 (CYP) andplasma protein binding.
In vivo assessment of drug−drug interactions
The drug-drug interaction studies were performed at steady state with liraglutide 1.8 mg/day. The effect on rateof gastric emptying was equivalent between liraglutide 1.8 mg and 3 mg (acetaminophen AUC0-300min).
Administration of the interacting drugs was timed so that Cmax of liraglutide (8-12 h) would coincide with theabsorption peak of the co-administered drugs.
Oral Contraceptives
A single dose of an oral contraceptive combination product containing 0.03 mg ethinylestradiol and 0.15 mg
levonorgestrel was administered under fed conditions and 7 hours after the dose of liraglutide at steady state.
Liraglutide lowered ethinylestradiol and levonorgestrel Cmax by 12% and 13%, respectively. There was no effectof liraglutide on the overall exposure (AUC) of ethinylestradiol. Liraglutide increased the levonorgestrel
AUC0-∞ by 18%. Liraglutide delayed Tmax for both ethinylestradiol and levonorgestrel by 1.5 h.
1

Reference ID: 3677762

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

DigoxinA single dose of digoxin 1 mg was administered 7 hours after the dose of liraglutide at steady state. The
concomitant administration with liraglutide resulted in a reduction of digoxin AUC by 16%; Cmax decreased by
31%. Digoxin median time to maximal concentration (Tmax) was delayed from 1 h to 1.5 h.
Lisinopril
A single dose of lisinopril 20 mg was administered 5 minutes after the dose of liraglutide at steady state. The
co-administration with liraglutide resulted in a reduction of lisinopril AUC by 15%; Cmax decreased by 27%.
Lisinopril median Tmax was delayed from 6 h to 8 h with liraglutide.
Atorvastatin
Liraglutide did not change the overall exposure (AUC) of atorvastatin following a single dose of atorvastatin 40
mg, administered 5 hours after the dose of liraglutide at steady state. Atorvastatin Cmax was decreased by 38%
and median Tmax was delayed from 1 h to 3 h with liraglutide.
Acetaminophen
Liraglutide did not change the overall exposure (AUC) of acetaminophen following a single dose of
acetaminophen 1000 mg, administered 8 hours after the dose of liraglutide at steady state. Acetaminophen Cmax
was decreased by 31% and median Tmax was delayed up to 15 minutes.
Griseofulvin
Liraglutide did not change the overall exposure (AUC) of griseofulvin following co-administration of a single
dose of griseofulvin 500 mg with liraglutide at steady state. Griseofulvin Cmax increased by 37% while medianTmax did not change.
Insulin Detemir
No pharmacokinetic interaction was observed between liraglutide and insulin detemir when separate
subcutaneous injections of insulin detemir 0.5 Unit/kg (single-dose) and liraglutide 1.8 mg (steady state) wereadministered to patients with type 2 diabetes mellitus.
13
NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
A 104-week carcinogenicity study was conducted in male and female CD-1 mice at doses of 0.03, 0.2, 1, and 3
mg/kg/day liraglutide administered by bolus subcutaneous injection yielding systemic exposures 0.2-, 2-, 10and 43-times the exposure in obese humans, respectively, at the maximum recommended human dose (MRHD)of 3 mg/day based on plasma AUC comparison. A dose-related increase in benign thyroid C-cell adenomas wasseen in the 1 and the 3 mg/kg/day groups with incidences of 13% and 19% in males and 6% and 20% in
females, respectively. C-cell adenomas did not occur in control groups or 0.03 and 0.2 mg/kg/day groups.
Treatment-related malignant C-cell carcinomas occurred in 3% of females in the 3 mg/kg/day group. Thyroid
C-cell tumors are rare findings during carcinogenicity testing in mice. A treatment-related increase infibrosarcomas was seen on the dorsal skin and subcutis, the body surface used for drug injection, in males in the
3 mg/kg/day group. These fibrosarcomas were attributed to the high local concentration of drug near the
injection site. The liraglutide concentration in the clinical formulation (6 mg/mL) is 10-times higher than theconcentration in the formulation used to administer 3 mg/kg/day liraglutide to mice in the carcinogenicity study(0.6 mg/mL).
A 104-week carcinogenicity study was conducted in male and female Sprague Dawley rats at doses of 0.075,
0.25 and 0.75 mg/kg/day liraglutide administered by bolus subcutaneous injection with exposures 0.5-, 2- and7-times the exposure in obese humans, respectively, resulting from the MRHD based on plasma AUC
comparison. A treatment-related increase in benign thyroid C-cell adenomas was seen in males in 0.25 and 0.75
1Reference ID: 3677762

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

mg/kg/day liraglutide groups with incidences of 12%, 16%, 42%, and 46% and in all female liraglutide-treatedgroups with incidences of 10%, 27%, 33%, and 56% in 0 (control), 0.075, 0.25, and 0.75 mg/kg/day groups,
respectively. A treatment-related increase in malignant thyroid C-cell carcinomas was observed in all maleliraglutide-treated groups with incidences of 2%, 8%, 6%, and 14% and in females at 0.25 and 0.75 mg/kg/day
with incidences of 0%, 0%, 4%, and 6% in 0 (control), 0.075, 0.25, and 0.75 mg/kg/day groups, respectively.
Thyroid C-cell carcinomas are rare findings during carcinogenicity testing in rats.
Studies in mice demonstrated that liraglutide-induced C-cell proliferation was dependent on the GLP-1 receptor
and that liraglutide did not cause activation of the REarranged during Transfection (RET) proto-oncogene inthyroid C-cells.
Human relevance of thyroid C-cell tumors in mice and rats is unknown and has not been determined by clinicalstudies or nonclinical studies [see Boxed Warning and Warnings and Precautions (5.1)].
Liraglutide was negative with and without metabolic activation in the Ames test for mutagenicity and in ahuman peripheral blood lymphocyte chromosome aberration test for clastogenicity. Liraglutide was negative in
repeat-dose in vivo micronucleus tests in rats.
In rat fertility studies using subcutaneous doses of 0.1, 0.25 and 1 mg/kg/day liraglutide, males were treated for
4 weeks prior to and throughout mating and females were treated 2 weeks prior to and throughout mating until
gestation day 17. No direct adverse effects on male fertility was observed at doses up to 1 mg/kg/day, a highdose yielding an estimated systemic exposure 11-times the exposure in obese humans at the MRHD, based on
plasma AUC comparison. In female rats, an increase in early embryonic deaths occurred at 1 mg/kg/day.
Reduced body weight gain and food consumption were observed in females at the 1 mg/kg/day dose.
14
CLINICAL STUDIESThe safety and efficacy of Saxenda for chronic weight management in conjunction with reduced caloric intake
and increased physical activity were studied in three 56-week, randomized, double-blind, placebo-controlled
trials. In all studies, Saxenda was titrated to 3 mg daily during a 4-week period. All patients received instruction
for a reduced calorie diet (approximately 500 kcal/day deficit) and exercise counseling (recommended increasein physical activity of minimum 150 mins/week) that began with the first dose of study medication or placeboand continued throughout the trial.
Study 1 was a 56-week trial that enrolled 3731 patients with obesity (BMI greater than or equal to 30 kg/m2) orwith overweight (BMI 27-29.9 kg/m2) and at least one weight-related comorbid condition such as treated or
untreated dyslipidemia or hypertension; patients with type 2 diabetes mellitus were excluded. Patients wererandomized in a 2:1 ratio to either Saxenda or placebo. The mean age was 45 years (range 18-78), 79% were
women, 85% were Caucasian, 10% were African American, and 11% were Hispanic/Latino. Mean baseline
body weight was 106.3 kg and mean BMI was 38.3 kg/m2.
Study 2 was a 56-week trial that enrolled 635 patients with type 2 diabetes and with either overweight orobesity (as defined above). Patients were to have an HbA1c of 7-10% and be treated with metformin, asulfonylurea, or a glitazone as single agent or in any combination, or with diet and exercise alone. Patients wererandomized in a 2:1 ratio to receive either Saxenda or placebo. The mean age was 55 years (range 18-82), 50%
were women, 83% were Caucasian, 12% were African American, and 10% were Hispanic/Latino. Meanbaseline body weight was 105.9 kg and mean BMI was 37.1 kg/m2.
Study 3 was a 56-week trial that enrolled 422 patients with obesity (BMI greater than or equal to 30 kg/m2) orwith overweight (BMI 27-29.9 kg/m2) and at least one weight-related comorbid condition such as treated or
untreated dyslipidemia or hypertension; patients with type 2 diabetes mellitus were excluded. All patients were
1

Reference ID: 3677762

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

first treated with a low-calorie diet (total energy intake 1200-1400 kcal/day) in a run-in period lasting up to 12
weeks. Patients who lost at least 5% of their screening body weight after 4 to 12 weeks during the run-in werethen randomized, with equal allocation, to receive either Saxenda or placebo for 56 weeks. The mean age was
46 years (range 18-73), 81% were women, 84% were Caucasian, 13% were African American, and 7% wereHispanic/Latino. Mean baseline body weight was 99.6 kg and mean BMI was 35.6 kg/m2.
The proportions of patients who discontinued study drug in the 56-week trials were 27% for the Saxenda-treatedgroup and 35% for the placebo-treated group. Approximately 10% of patients treated with Saxenda and 4% of
patients treated with placebo discontinued treatment due to an adverse reaction [see Adverse Reactions (6.1)].
The majority of patients who discontinued Saxenda due to adverse reactions did so during the first few monthsof treatment.
Effect of Saxenda on Body Weight
For Study 1 and Study 2, the primary efficacy parameters were mean percent change in body weight and thepercentages of patients achieving greater than or equal to 5% and 10% weight loss from baseline to week 56.
For Study 3, the primary efficacy parameters were mean percent change in body weight from randomization to
week 56, the percentage of patients not gaining more than 0.5% body weight from randomization (i.e., after runin) to week 56, and the percentage of patients achieving greater than or equal to 5% weight loss fromrandomization to week 56. Because losing at least 5% of fasting body weight through lifestyle intervention
during the 4- to 12-week run-in was a condition for their continued participation in the randomized treatment
period, the results may not reflect those expected in the general population.
Table 4 presents the results for the changes in weight observed in Studies 1, 2, and 3. After 56 weeks, treatment
with Saxenda resulted in a statistically significant reduction in weight compared with placebo. Statisticallysignificantly greater proportions of patients treated with Saxenda achieved 5% and 10% weight loss than thosetreated with placebo. In Study 3, statistically significantly more patients randomized to Saxenda than placebo
had not gained more than 0.5% of body weight from randomization to week 56.
Table 4.

Changes in Weight at Week 56 for Studies 1, 2, and 3
Study 2 (Type 2
Study 1 (Obesity or
diabetes with obesity
overweight withcomorbidity)
or overweight)

WeightBaseline mean (SD) (kg)Percent change frombaseline (LSMean)
Difference from placebo(LSMean) (95% CI)% of Patients losing greaterthan or equal to 5% bodyweightDifference from placebo(LSMean) (95% CI)
1

Reference ID: 3677762

Study 3 (Obesity or
overweight withcomorbidity following
at least 5% weight loss
with diet)
SaxendaPlacebo
N=212
N=210

Saxenda
N=2487

Placebo
N=1244

Saxenda
N=423

Placebo
N=212

106.2
(21.2)

106.2(21.7)

105.7(21.9)

106.5(21.3)

100.4(20.8)

98.7(21.2)

-7.4

-3.0

-5.4

-1.7

-4.9

0.3

-4.5*
(-5.2;-3.8)
62.3%
27.9*
(23.9;31.9)-3.7*(-4.7;-2.7)
34.4%

49.0%
32.6*
(25.1;40.1)-5.2*(-6.8;-3.5)
16.4%

44.2%
22.6*
(13.9;31.3)

21.7%

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda% of Patients losing greaterthan 10% body weight
Difference from placebo(LSMean) (95% CI)

33.9%
18.5*
(15.2;21.7)

15.4%

22.4%
16.9*
(11.7;22.1)

5.5%

25.4%

6.9%

18.5*
(11.7;25.3)

SD = Standard Deviation; CI = Confidence Interval* p < 0.0001 compared to placebo. Type 1 error was controlled across the three endpoints.
Includes all randomized subjects who had a baseline body weight measurement. All available body weight data during the 56 weektreatment period are included in the analysis. In Studies 1 and 2 missing values for week 56 were handled using multiple imputations
analysis. In Study 3 missing values for week 56 were handled using weighted regression analysis.

The cumulative frequency distributions of change in body weight from baseline to week 56 are shown in Figure
2 for Studies 1 and 2. One way to interpret this figure is to select a change in body weight of interest on thehorizontal axis and note the corresponding proportions of patients (vertical axis) in each treatment group who
achieved at least that degree of weight loss. For example, note that the vertical line arising from -10% in Study
1 intersects the Saxenda and placebo curves at approximately 34% and 15%, respectively, which correspond tothe values shown in Table 4.

Figure 2.

Change in body weight (%) from baseline to week 56 (Study 1 on left and Study 2 on right)

The time courses of weight loss with Saxenda and placebo from baseline through week 56 are depicted in
Figures 3 and 4.

Figure 3.

Change from baseline (%) in body weight (Study 1 on left and Study 2 on right)

1

Reference ID: 3677762

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

Figure 4.

Change from baseline (%) in body weight during Study 3

Effect of Saxenda on Anthropometry and Cardiometabolic Parameters
Changes in waist circumference and cardiometabolic parameters with Saxenda are shown in Table 5 for Study 1(patients without diabetes mellitus) and Table 6 for Study 2 (patients with type 2 diabetes). Results from Study3, which also enrolled patients without diabetes mellitus, were similar to Study 1.
Table 5.

Mean Changes in Anthropometry and Cardiometabolic Parameters in Study 1 (Patients
without Diabetes)
SaxendaPlacebo
N = 2487
N = 1244
ChangeChangeSaxenda minus
Baseline
Baselinefrom
from
PlaceboBaseline
Baseline(LSMean)(LSMean1)(LSMean1)
Waist Circumference (cm)
115.0
-8.2
114.5
-4.0
-4.2
Systolic blood pressure (mmHg)
123.0
-4.3
123.3
-1.5
-2.8
Diastolic blood pressure (mmHg)
78.7
-2.7
78.9
-1.8
-0.9
Heart Rate (bpm)
71.4
2.6
71.3
0.1
2.5
Relative% change% change
Difference ofBaselinefromBaselinefrom
Saxenda toBaseline
Baseline
Placebo(LSMean1)(LSMean1)(LSMean)Total Cholesterol (mg/dL)*
-3.2
-0.9
-2.3
193.8
194.4
LDL Cholesterol (mg/dL)*
-3.1
-0.7
-2.4
111.8
112.3
HDL Cholesterol (mg/dL)*
2.3
0.5
1.9
51.4
50.9
Triglycerides (mg/dL)†
-13.0
-4.1
-7.1
125.7
128.3
Based on last observation carried forward method while on study drug
1
Least squares mean adjusted for treatment, country, sex, pre-diabetes status at screening, baseline BMI stratum and an interaction
between pre-diabetes status at screening and BMI stratum as fixed factors, and the baseline value as covariate.
* Baseline value is the geometric mean
†Values are baseline median, median % change, and the Hodges-Lehmann estimate of the median treatment difference.

1

Reference ID: 3677762

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

Table 6.

Mean Changes in Anthropometry and Cardiometabolic Parameters in Study 2 (Patientswith Diabetes Mellitus)
SaxendaPlacebo
N = 423
N = 212
ChangeChangeSaxenda minus
from
from
Baseline
PlaceboBaseline
Baseline
Baseline(LSMean)1
1(LSMean )(LSMean )Waist Circumference (cm)
118.1
-6.0
117.3
-2.8
-3.2
Systolic Blood Pressure
128.9
-3.0
129.2
-0.4
-2.6
(mmHg)
Diastolic Blood Pressure
79.0
-1.0
79.3
-0.6
-0.4
(mmHg)
Heart Rate (bpm)
74.0
2.0
74.0
-1.5
3.4
% change% change
Relative Difference
from
from
of Saxenda toBaseline
Baseline
Baseline
Baseline
Placebo1
1(LSMean )(LSMean )(LSMean)Total Cholesterol (mg/dL)*
171.0
-1.4
169.4
2.4
-3.7
LDL Cholesterol (mg/dL)*
86.4
0.9
85.2
3.3
-2.3
HDL Cholesterol (mg/dL)*
45.2
4.8
45.4
1.9
2.9
Triglycerides (mg/dL)†
156.2
-14.5
155.8
-0.7
-13.5
Based on last observation carried forward method while on study drug
Least squares mean adjusted for treatment, country, sex, background treatment, baseline HbA1c stratum and an interaction between
background treatment and HbA1c stratum as fixed factors, and the baseline value as covariate.
* Baseline value is the geometric mean
†Values are baseline median, median % change, and the Hodges-Lehmann estimate of the median treatment difference.
1

16
HOW SUPPLIED/STORAGE AND HANDLING
16.1 How Supplied
Saxenda is available in the following package sizes containing disposable, pre-filled, multi-dose pens. Eachindividual pen delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg or 3 mg (6 mg/mL, 3 mL).
3 x Saxenda pen NDC 0169-2800-13
5 x Saxenda pen NDC 0169-2800-15
Each Saxenda pen is for use by a single patient. A Saxenda pen should never be shared between patients, even if
the needle is changed.
16.2 Recommended Storage
Prior to first use, Saxenda should be stored in a refrigerator between 36ºF to 46ºF (2ºC to 8ºC) (Table 7). Do notstore in the freezer or directly adjacent to the refrigerator cooling element. Do not freeze Saxenda and do not
use Saxenda if it has been frozen.
After initial use of the Saxenda pen, the pen can be stored for 30 days at controlled room temperature (59°F to
86°F; 15°C to 30°C) or in a refrigerator (36°F to 46°F; 2°C to 8°C). Keep the pen cap on when not in use.
Saxenda should be protected from excessive heat and sunlight. Always remove and safely discard the needle
after each injection and store the Saxenda pen without an injection needle attached. This will reduce thepotential for contamination, infection, and leakage while also ensuring dosing accuracy.
1

Reference ID: 3677762

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

Table 7.

Recommended Storage Conditions for Saxenda
Prior to first use
After first use
Refrigerated
Room Temperature
Refrigerated
36°F to 46°F
59°F to 86°F
36°F to 46°F
(2°C to 8°C)
(15°C to 30°C)(2°C to 8°C)
Until expiration date
30 days

17
PATIENT COUNSELING INFORMATION
17.1 FDA-Approved Medication Guide
See FDA-Approved Medication Guide.
17.2 Instructions
Saxenda is indicated for chronic weight management in conjunction with a reduced-calorie diet and increased
physical activity.
Advise patients to take Saxenda exactly as prescribed. Patients should be instructed to follow the dose
escalation schedule and not to take more than the recommended dose of Saxenda.
Instruct patients to discontinue use of Saxenda if they have not achieved 4% weight loss by 16 weeks oftreatment.
17.3 Risk of Thyroid C-cell Tumors
Inform patients that liraglutide causes benign and malignant thyroid C-cell tumors in mice and rats and that thehuman relevance of this finding has not been determined. Counsel patients to report symptoms of thyroid
tumors (e.g., a lump in the neck, hoarseness, dysphagia or dyspnea) to their physician [see Boxed Warning andWarnings and Precautions (5.1)].
17.4 Acute Pancreatitis
Patients should be informed of the potential risk for acute pancreatitis. Explain that persistent severe abdominal
pain that may radiate to the back and which may or may not be accompanied by vomiting, is the hallmark
symptom of acute pancreatitis. Instruct patients to discontinue Saxenda promptly and contact their physician if
persistent severe abdominal pain occurs.
17.5 Acute Gallbladder Disease
Patients should be informed that substantial or rapid weight loss can increase the risk of cholelithiasis.
Cholelithiasis may also occur in the absence of substantial or rapid weight loss. Patients should be instructed tocontact their physician if cholelithiasis is suspected for appropriate clinical follow-up.
17.6 Hypoglycemia in Patients with Type 2 Diabetes Mellitus on Anti-Diabetic Therapy
Patients with type 2 diabetes mellitus on anti-diabetic therapy should be advised to monitor their blood glucose
levels and report symptoms of hypoglycemia to their physician.
17.7 Heart Rate Increase
Patients should be informed to report symptoms of sustained periods of heart pounding or racing while at restto their physician. For patients who experience a sustained increase in resting heart rate while taking Saxenda,
Saxenda should be discontinued.
17.8

Dehydration and Renal Impairment
1

Reference ID: 3677762

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

Patients treated with Saxenda should be advised of the potential risk of dehydration due to gastrointestinal
adverse reactions and take precautions to avoid fluid depletion. Patients should be informed of the potential risk
for worsening renal function, which in some cases may require dialysis.
17.9 Hypersensitivity Reactions
Patients should be informed that serious hypersensitivity reactions have been reported during use of liraglutide.
If symptoms of hypersensitivity reactions occur, patients must stop taking Saxenda and seek medical advice
promptly.
17.10 Suicidal Behavior and Ideation
Patients treated with Saxenda should be advised to report emergence or worsening of depression, suicidal
thoughts or behavior, and/or any unusual changes in mood or behavior. Patients should be informed that if theyexperience suicidal thoughts or behaviors, Saxenda should be discontinued.
17.11 Jaundice and Hepatitis
Inform patients that jaundice and hepatitis have been reported during postmarketing use of liraglutide. Instructpatients to contact their physician if they develop jaundice.
17.12 Never Share a Saxenda Pen Between Patients
Patients should be informed that they should never share a Saxenda pen with another person, even if the needle
is changed. Sharing of the pen between patients may pose a risk of transmission of infection.
Version: 1
Saxenda® and Victoza® are registered trademarks of Novo Nordisk A/S.
Saxenda® is covered by US Patent Nos. 6,268,343, 6,458,924, 7,235,627, 8,114,833 and other patents pending.
Saxenda® pen is covered by US Patent Nos. 6,899,699, 7,686,786, 8,672,898, 8,684,969 and other patents
pending.
© 2014 Novo Nordisk
Manufactured by:
Novo Nordisk A/S
DK-2880 Bagsvaerd, Denmark
For information about Saxenda contact:
Novo Nordisk Inc.
800 Scudders Mill Road
Plainsboro, NJ 08536
1-844-363-4448

1

Reference ID: 3677762

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

Medication Guide
Saxenda® (sax-end-ah)(liraglutide [rDNA origin])
Injection
Read this Medication Guide and Patient Instructions for Use that come with
Saxenda before you start using Saxenda and each time you get a refill. Theremay be new information. This Medication Guide does not take the place oftalking with your healthcare provider about your medical condition or yourtreatment. If you have questions about Saxenda after reading thisinformation, ask your healthcare provider or pharmacist.
What is the most important information I should know about
Saxenda?
Serious side effects may happen in people who take Saxenda, including:
1. Possible thyroid tumors, including cancer. During the drug testingprocess, the medicine in Saxenda caused rats and mice to develop tumorsof the thyroid gland. Some of these tumors were cancers. It is not known
if Saxenda will cause thyroid tumors or a type of thyroid cancer called
medullary thyroid cancer in people. If medullary thyroid cancer occurs, it
may lead to death if not detected and treated early. If you develop
tumors or cancer of the thyroid, your thyroid may have to be surgicallyremoved.
• Before you start taking Saxenda, tell your healthcare provider if youor any of your family members have had thyroid cancer, especiallymedullary thyroid cancer, or Multiple Endocrine Neoplasia syndrome
type 2. Do not take Saxenda if you or any of your family members
have medullary thyroid cancer, or if you have Multiple Endocrine
Neoplasia syndrome type 2. People with these conditions alreadyhave a higher chance of developing medullary thyroid cancer ingeneral and should not take Saxenda.
• While taking Saxenda, tell your healthcare provider if you get a lumpor swelling in your neck, hoarseness, trouble swallowing, orshortness of breath. These may be symptoms of thyroid cancer.
2. Inflammation of the pancreas (pancreatitis), which may be severe
and lead to death.
Before taking Saxenda, tell your healthcare provider if you have
had:
•
•
•
•

pancreatitis
stones in your gallbladder (gallstones)a history of alcoholism
high blood triglyceride levels

These medical conditions can make you more likely to get pancreatitis in
general. It is not known if having these conditions will lead to a higher
chance of getting pancreatitis while taking Saxenda.

Reference ID: 3677762

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

While taking Saxenda:
Stop taking Saxenda and call your healthcare provider right away if you havepain in your stomach area (abdomen) that is severe and will not go away.
The pain may happen with or without vomiting. The pain may be felt goingfrom your abdomen through to your back. This type of pain may be asymptom of pancreatitis.
What is Saxenda?
•

Saxenda is an injectable prescription medicine that may help some obese
adults or overweight adults who also have weight related medical
problems lose weight and keep the weight off.

•

Saxenda should be used with a reduced calorie diet and increased
physical activity.

•

Saxenda is not for the treatment of type 2 diabetes mellitus.

•

Saxenda and Victoza® have the same active ingredient, liraglutide.
Saxenda and Victoza should not be used together.

•

Saxenda should not be used with other GLP-1 receptor agonist medicines.

•

Saxenda and insulin should not be used together.

•

It is not known if Saxenda is safe and effective when taken with otherprescription, over-the-counter, or herbal weight loss products.

•

It is not known if Saxenda changes your risk of heart problems or stroke
or of death due to heart problems or stroke.

•

It is not known if Saxenda can be used safely in people who have hadpancreatitis.

•

It is not known if Saxenda is safe and effective in children under 18 yearsof age. Saxenda is not recommended for use in children.

Who should not use Saxenda?
Do not use Saxenda if:•

you or any of your family members have a history of medullary thyroid
cancer.

•you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This isa disease where people have tumors in more than one gland in their
body.

•

you are allergic to liraglutide or any of the ingredients in Saxenda. See
the end of this Medication Guide for a complete list of ingredients in
Saxenda.
Symptoms of a serious allergic reaction may include:

Reference ID: 3677762oswelling of your face, lips, tongue, or throatofainting or feeling dizzyThis label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

overy rapid heartbeatoproblems breathing or swallowingosevere rash or itching

Talk with your healthcare provider if you are not sure if you have any ofthese conditions.
•are pregnant or planning to become pregnant. Saxenda may harm yourunborn baby.

What should I tell my healthcare provider before using Saxenda?
Before taking Saxenda, tell your healthcare provider if you:• have any of the conditions listed in the section “What is the mostimportant information I should know about Saxenda?”•

are taking certain medications called GLP-1 receptor agonists.

• are allergic to liraglutide or any of the other ingredients in Saxenda. See
the end of this Medication Guide for a list of ingredients in Saxenda.
•

have severe problems with your stomach, such as slowed emptying ofyour stomach (gastroparesis) or problems with digesting food.

•have or have had kidney or liver problems.

•

have or have had depression or suicidal thoughts.

•

have any other medical conditions.

•are pregnant or plan to become pregnant. Saxenda may harm yourunborn baby. Tell your healthcare provider if you become pregnant while
taking Saxenda. If you are pregnant you should stop using Saxenda.

•

are breastfeeding or plan to breastfeed. It is not known if Saxenda
passes into your breast milk. You and your healthcare provider should
decide if you will take Saxenda or breastfeed. You should not do bothwithout talking with your healthcare provider first.

Tell your healthcare provider about all the medicines you take including
prescription and non-prescription medicines, vitamins, and herbal
supplements. Saxenda slows stomach emptying and can affect medicinesthat need to pass through the stomach quickly. Saxenda may affect the way
some medicines work and some other medicines may affect the way Saxenda
works. Tell your healthcare provider if you take other diabetes medicines,
especially sulfonylurea medicines or insulin.
Know the medicines you take. Keep a list of them with you to show yourhealthcare provider and pharmacist each time you get a new medicine.
How should I use Saxenda?
•

Use Saxenda exactly as prescribed by your healthcare provider. Your
dose should be increased after using Saxenda for 1 week until you reach

Reference ID: 3677762

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

the 3 mg dose. After that, do not change your dose unless yourhealthcare provider tells you to.
•

Saxenda is injected 1 time each day, at any time during the day.

•You can take Saxenda with or without food.

•Your doctor should start you on a diet and exercise program when you
start taking Saxenda. Stay on this program while you are taking
Saxenda.

•Saxenda comes in a prefilled pen.

•Your healthcare provider must teach you how to inject Saxenda before
you use it for the first time. If you have questions or do not understandthe instructions, talk to your healthcare provider or pharmacist. See thePatient Instructions for Use that come with this Medication Guide fordetailed information about the right way to use your Saxenda pen.

•Pen needles are not included. Use the Saxenda pen with Novo Nordisk
disposable needles. You may need a prescription to get pen needles fromyour pharmacist. Ask your healthcare provider which needle size is bestfor you.

•

When starting a new prefilled Saxenda pen, you must follow the “Check
the Saxenda flow with each new pen” (see the detailed Patient
Instructions for Use that comes with this Medication Guide). You only
need to do this 1 time with each new pen. You should also do this if you
drop your pen. If you do the “Check the Saxenda flow with each newpen” before each injection, you will run out of medicine too soon.

•

Inject your dose of Saxenda under the skin (subcutaneous injection) in
your stomach area (abdomen), upper leg (thigh), or upper arm, as
instructed by your healthcare provider. Do not inject into a vein or
muscle.

•If you take too much Saxenda, call your healthcare provider right away.
Too much Saxenda may cause severe nausea and vomiting.

•If you miss your daily dose of Saxenda, use Saxenda as soon as you
remember. Then take your next daily dose as usual on the following day.
Do not take an extra dose of Saxenda or increase your dose on thefollowing day to make up for your missed dose. If you miss your dose of
Saxenda for 3 days or more, call your healthcare provider to talk about
how to restart your treatment.

•

Never share your Saxenda pen or needles with another person. You may
give an infection to them, or get an infection from them.

What are the possible side effects of Saxenda?
Saxenda may cause serious side effects, including:•possible thyroid tumors, including cancer. See “What is the mostimportant information I should know about Saxenda?”•

inflammation of the pancreas (pancreatitis). See “What is the mostimportant information I should know about Saxenda?”

Reference ID: 3677762

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda•

gallbladder problems. Saxenda may cause gallbladder problems
including gallstones. Some gallbladder problems need surgery. Call yourhealthcare provider if you have any of the following symptoms:• pain in your upper stomach (abdomen)• fever• yellowing of your skin or eyes (jaundice)• clay-colored stools• low blood sugar (hypoglycemia) in people with type 2 diabetes
mellitus who also take medicines to treat type 2 diabetes mellitus.
Saxenda can cause low blood sugar in people with type 2 diabetes mellitus
who also take medicines used to treat type 2 diabetes mellitus (such as
sulfonylureas). In some people, the blood sugar may get so low that theyneed another person to help them. If you take a sulfonylurea medicine,the dose may need to be lowered while you use Saxenda. Signs andsymptoms of low blood sugar may include:•

shakiness•

confusion•

sweating•

irritability•

headache•hunger•drowsiness•fast heartbeat•

weakness•feeling jittery•

dizziness

Talk to your healthcare provider about how to recognize and treat low
blood sugar. Make sure that your family and other people who are around
you a lot know how to recognize and treat low blood sugar. You should
check your blood sugar before you start taking Saxenda and while you
take Saxenda.
•

increased heart rate. Saxenda can increase your heart rate while you
are at rest. Your healthcare provider should check your heart rate while
you take Saxenda. Tell your healthcare provider if you feel your heart
racing or pounding in your chest and it lasts for several minutes when
taking Saxenda.

•

kidney problems (kidney failure). Saxenda may cause nausea,
vomiting or diarrhea leading to loss of fluids (dehydration). Dehydration
may cause kidney failure which can lead to the need for dialysis. This canhappen in people who have never had kidney problems before. Drinking
plenty of fluids may reduce your chance of dehydration.

Call your healthcare provider right away if you have nausea, vomiting, or
diarrhea that does not go away, or if you cannot drink liquids by mouth.
•

serious allergic reactions. Serious allergic reactions can happen with
Saxenda. Stop using Saxenda, and get medical help right away if you

Reference ID: 3677762

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

have any symptoms of a serious allergic reaction See “Who should not
use Saxenda?”•

depression or thoughts of suicide. You should pay attention to any
mental changes, especially sudden changes, in your mood, behaviors,
thoughts, or feelings. Call your healthcare provider right away if you
have any mental changes that are new, worse, or worry you.

Common side effects of Saxenda include:
•
•
•
•
•
•
•
•
•
•
•
•

nauseadiarrhea
constipation
low blood sugar (hypoglycemia)
vomiting
headachedecreased appetite
upset stomach
tirednessdizzinessstomach painchanges in enzyme (lipase) levels in your blood

Nausea is most common when first starting Saxenda, but decreases overtime in most people as their body gets used to the medicine.
Tell your healthcare provider if you have any side effect that bothers you orthat does not go away.
These are not all the side effects with Saxenda. For more information, ask
your healthcare provider or pharmacist.
Call your doctor for medical advice about side effects. You may report side
effects to FDA at 1-800-FDA-1088.
Keep your Saxenda pen, pen needles, and all medicines out of thereach of children.
General information about the safe and effective use of Saxenda.
Medicines are sometimes prescribed for purposes other than those listed in a
Medication Guide. Do not use Saxenda for a condition for which it was notprescribed. Do not give Saxenda to other people, even if they have the same
symptoms you have. It may harm them.
This Medication Guide summarizes the most important information you
should know about using Saxenda. If you would like more information, talkwith your healthcare provider. You can ask your pharmacist or healthcare
provider for information about Saxenda that is written for healthprofessionals.
For more information, go to saxenda.com or call 1-844-363-4448.

Reference ID: 3677762

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

What are the ingredients in Saxenda?
Active Ingredient: liraglutide
Inactive Ingredients: disodium phosphate dihydrate, propylene glycol,
phenol and water for injection

For more information go to www.saxenda.com
Manufactured by:
Novo Nordisk A/S
DK-2880 Bagsvaerd, Denmark
For information about Saxenda contact:
Novo Nordisk Inc.
800 Scudders Mill Road
Plainsboro, NJ 08536
1-844-363-4448
Issued: December 2014
Version: 1
This Medication Guide has been approved by the U.S. Food and Drug
Administration.
Saxenda®, Victoza®, NovoFine®, and NovoTwist® are registered trademarksof Novo Nordisk A/S.
Saxenda® is covered by US Patent Nos. 6,268,343, 6,458,924, 7,235,627
and 8,114,833 and other patents pending.
Saxenda® pen is covered by US Patent Nos. 6,899,699, 7,686,786,
8,672,898, 8,684,969 and other patents pending.
© 2014 Novo Nordisk

Reference ID: 3677762

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

Reference ID: 3677762

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

•
•

•
•

•

Instructions for Use
Read these instructions carefully before using your Saxenda® pen.
Do not use your pen without proper training from your healthcare
provider. Make sure that you know how to give yourself an injection withthe pen before you start your treatment.
If you are blind or have poor eyesight and cannot read the dosecounter on the pen, do not use this pen without help. Get help froma person with good eyesight who is trained to use the Saxenda pen.
You can refresh your training at any time by watching the online
training video at www.saxenda.com.
Start by checking your pen to make sure that it contains Saxenda,
then look at the pictures below to get to know the different partsof your pen and needle.
Your pen is a prefilled dial-a-dose pen. It contains 18 mg ofliraglutide, and you can select doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg
and 3 mg. Your pen is made to be used with NovoFine® or NovoTwist®
disposable needles up to a length of 8 mm.

Saxenda pen and needle(example)
NovoFine
Pen cap

Outer
needle cap
Innerneedle cap

NeedlePapertab
Pen scalePen window

NovoTwist
Outer
needle cap
Innerneedle cap
Needle

Dose counter
Dose pointerDose selector
Dose button

Reference ID: 3677762

Paper
tab
Flow
check
symbolThis label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

Step 1. Prepare your pen with a new needle•
Wash your hands with soap and water.
•
Check the name and colored label of your pen, to makesure that it contains Saxenda. This is especially important if
you take more than 1 type of medicine.
•
Pull off the pen cap.

•

Check that Saxenda in your pen is clear and colorless.
Look through the pen window. If Saxenda looks cloudy, do
not use the pen.

•Take a new needle, and tear off the paper tab.

•Push the needle straight onto the pen. Turn until it ison tight.

•

Pull off the outer needle cap. Do not throw it away.

•

Pull off the inner needle cap and throw it away.
A drop of Saxenda may appear at the needle tip. This isnormal, but you must still check the Saxenda flow, if you
use a new pen for the first time.
Always use a new needle for each injection.
This will prevent contamination, infection, leakage of
Saxenda, and blocked needles leading to the wrong dose.
Never use a bent or damaged needle.
Do not attach a new needle to your pen until you areready to take your injection.

Reference ID: 3677762

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

Step 2. Check the Saxenda flow with each new pen.
•
Check the Saxenda flow before your first injection witheach new pen.
If your Saxenda pen is already in use, go to Step 3 “Selectyour dose”.
•
Turn the dose selector until the dose counter shows theflow check symbol ().
••

Hold the pen with the needle pointing up.
Press and hold in the dose button until the dosecounter shows 0. The 0 must line up with the dose pointer.
A drop of Saxenda will appear at the needle tip.
If no drop appears, repeat Step 2 above as shown in
Figures G and H up to 6 times. If there is still no drop,change the needle and repeat Step 2 as shown in Figures G
and H 1 more time.
Do not use the pen if a drop of Saxenda still does notappear. Contact Novo Nordisk at 1-877-484-2869.
Always make sure that a drop appears at the needle tip
before you use a new pen for the first time. This makes
sure that Saxenda flows.
If no drop appears, you will not inject any Saxenda, eventhough the dose counter may move. This may mean that
there is a blocked or damaged needle.
A small drop may remain at the needle tip, but it will not be
injected.
Only check the Saxenda flow before your first
injection with each new pen.

Step 3. Select your dose•
Turn the dose selector until the dose counter shows
your dose (0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg or 3 mg).
Make sure you know the dose of Saxenda you should use.
If you select the wrong dose, you can turn the dose
selector forward or backwards to the correct dose.
Always use the dose counter and the dose pointer tosee how many mg you select.
You will hear a “click” every time you turn the dose
selector. Do not set the dose by counting the numberof clicks you hear.
Do not use the pen scale to set the dose. It does not show
exactly how much Saxenda is left in your pen.
Only doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg or 3 mg
can be selected with the dose selector. The selected
dose must line up exactly with the dose pointer to makesure that you get a correct dose.
The dose selector changes the dose. Only the dose counter

Reference ID: 3677762

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

and dose pointer will show how many mg you select foreach dose.
You can select up to 3 mg each dose. When your pen
contains less than 3 mg the dose counter stops before 3
mg is shown.
The dose selector clicks differently when turned forward,
backwards or past the number of mg left. Do not count the
pen clicks.
••

How much Saxenda is left?
The pen scale shows you about how much Saxenda is leftin your pen.

To see how much Saxenda is left, use the dose counter:
Turn the dose selector until the dose counter stops.
If it shows 3, at least 3 mg are left in your pen. If thedose counter stops before 3 mg, there is not enough
Saxenda left for a full dose of 3 mg.

If you need more Saxenda than what is left in yourpen
Only if trained or told by your healthcare provider, you may split
your dose between your current pen and a new pen. Use acalculator to plan the doses as instructed by your healthcare
provider.
Be very careful to calculate correctly.
If you are not sure how to split your dose using 2 pens,then select and inject the dose you need with a new pen.
Step 4. Inject your dose•
Insert the needle into your skin as your healthcare
provider has shown you.
•
Make sure you can see the dose counter. Do not cover
it with your fingers. This could stop the injection.
•

Press and hold down the dose button until the dosecounter shows 0. The 0 must line up with the dosepointer. You may then hear or feel a click.

Reference ID: 3677762

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda•••

Keep the needle in your skin after the dose counter has
returned to 0 and count slowly to 6.
If the needle is removed earlier, you may see a stream of
Saxenda coming from the needle tip. If this happens, thefull dose will not be delivered.

Remove the needle from your skin.
If blood appears at the injection site, press lightly. Do not
rub the area.
Always watch the dose counter to know how many
mg you inject. Hold the dose button down until the dosecounter shows 0.
How to identify a blocked or damaged needle?
• If 0 does not appear in the dose counter after
continuously pressing the dose button, you may haveused a blocked or damaged needle.
• If this happens you have not received any Saxenda
even though the dose counter has moved from theoriginal dose that you have set.
How to handle a blocked needle?
Change the needle as described in Step 5, and repeat all
steps starting with Step 1: “Prepare your pen with a
new needle”. Make sure you select the full dose you need.
Never touch the dose counter when you inject. Thiscan stop the injection.

You may see a drop of Saxenda at the needle tip after
injecting. This is normal and does not affect your dose.
Step 5. After your injection••

Carefully remove the needle from the pen. Do not put
the needle caps back on the needle, to avoid needle sticks.

Place the needle in a sharps container right away to
reduce the risk of needle sticks.

Reference ID: 3677762

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

Put the pen cap on your pen after each use to protect
Saxenda from light.

•

If you do not have a sharps container, follow a 1-handed
needle recapping method. Carefully slip the needle into theouter needle cap. Dispose of the needle in a sharps
container as soon as possible.
Never try to put the inner needle cap back on theneedle. You may stick yourself with the needle.
Always remove the needle from your pen.
This prevents contamination, infection, leakage of Saxenda,
and blocked needles leading to the wrong dose. If theneedle is blocked, you will not inject any Saxenda.
Always dispose of the needle after each injection.
•

Do not throw away in the household trash. Put theneedle and any empty Saxenda pen or any pen used for
30 days still containing Saxenda in a FDA-cleared sharps
disposal container right away after use.

•

If you do not have a FDA-cleared sharps disposal
container, you may use a household container that is:omade of a heavy-duty plasticocan be closed with a tight-fitting, puncture-resistantlid, without sharps being able to come out uprightand stable during useoleak-resistantoproperly labeled to warn of hazardous waste inside
the container•

When your sharps disposal container is almost full, youwill need to follow your community guidelines for the right
way to dispose of your sharps disposal container. Theremay be state or local laws about how you should throw
away used needles and syringes. For more information
about the safe sharps disposal, and for specificinformation about sharps disposal in the state that youlive in, go to the FDA’s website at:
http://www.fda.gov/safesharpsdisposal•

Do not dispose of your used sharps disposal container inyour household trash unless your community guidelines
permit this. Do not recycle your used sharps disposal
container.

•

Safely dispose of Saxenda that is out of date or no longer

Reference ID: 3677762

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

needed.

•
•
•
•
•

•

ImportantCaregivers must be very careful when handling usedneedles to prevent needle sticks and cross infection.
Never use a syringe to withdraw Saxenda from your pen.
Always carry an extra pen and new needles with you,in case of loss or damage.
Always keep your pen and needles out of reach ofothers, especially children.
Do not share your Saxenda pen or needles withanyone else. You may give an infection to them or get an
infection from them.
Always keep your pen with you. Do not leave it in a caror other place where it can get too hot or too cold.

Caring for your pen•
Do not drop your pen or knock it against hard surfaces.
If you drop it or suspect a problem, attach a new needle
and check the Saxenda flow before you inject.
•

Do not try to repair your pen or pull it apart.

•

Do not expose your pen to dust, dirt or liquid.

•

Do not wash, soak, or lubricate your pen. If necessary,clean it with mild detergent on a moistened cloth.

How should I store my Saxenda pen?
•

Store your new, unused Saxenda pens in the refrigerator
at 36°F to 46°F (2°C to 8°C).

•

Store your pen in use for 30 days at 59ºF to 86ºF (15ºC
to 30ºC) or in a refrigerator at 36°F to 46°F (2°C to 8°C).

•

The Saxenda pen you are using should be thrown away
after 30 days, even if it still has Saxenda left in it.

•

Do not freeze Saxenda. Do not use Saxenda if it has beenfrozen.

•Unused Saxenda pens may be used until the expiration
date printed on the label, if kept in the refrigerator.

•

Keep Saxenda away from heat and out of the light.

This Medication Guide and Instructions for Use have been
approved by the U.S. Food and Drug Administration.
December 2014

Reference ID: 3677762

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda--------------------------------------------------------------------------------------------------------This is a representation of an electronic record that was signed
electronically and this page is the manifestation of the electronic
signature.
--------------------------------------------------------------------------------------------------------/s/---------------------------------------------------JAMES P SMITH
12/23/2014

Reference ID: 3677762